Statement from Sarah Yim, M.D., acting director of the Office of Therapeutic Biologics and Biosimilars in the FDA's Center for Drug Evaluation and Research, on FDA's continued progress facilitating competition in the biologic marketplace with approval of 25th biosimilar product - Herald-Mail Media

Statement from Sarah Yim, M.D., acting director of the Office of Therapeutic Biologics and Biosimilars in the FDA's Center for Drug Evaluation and Research, on FDA's continued progress facilitating competition in the biologic marketplace with approval of 25th biosimilar product  Herald-Mail Media

Comments

Popular posts from this blog

Epstein-Barr virus and autoimmune diseases

Chronic Lyme arthritis: A mystery solved?

Fibromyalgia — Latest Stories — Pain News Network